Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma

K.m. Kerr, S. J. MacKenzie, Graeme Ian Murray, M. C. Nicolson, George King, S. Ramasami, N. Fyfe, Andrea .d. Chapman

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Invasive parenchymal-type lung adenocarcinoma develops from atypical adenomatous hyperplasia (AAH), through an intermediate in situ stage of bronchioloalveolar carcinoma (BAC). We examined the expression of the putative tumour suppressor gene product Fhit, cell adhesion molecules CD44v6, E-cadherin and beta-catenin, and matrix metalloproteinase 2 and its inhibitor, TIMP-2, in a range of AAH lesions, BACs and invasive adenocarcinomas, to determine the changes in molecular expression associated with this form of neoplastic progression. Sections of formalin-fixed wax-embedded archival tissue were stained by standard Immunohistochemical techniques and scored semi-quantitatively, resulting in a grading of negative/low- or high-level staining. Fhit protein was retained at high levels in over 90% of AAH and 83% of BAC, but was found in only 6% of stromally invasive tumours (p < 0.0001). CD44v6 staining was high-level in 64% of AAH but fell to 26% in stromally invasive tumour (p = 0.007). E-cadherin and beta-catenin showed the opposite, with more highlevel staining as adenocarcinoma developed (p < 0.001). High-level MMP-2 and TIMP-2 expression was relatively infrequent in AAH (32% and 40% respectively), rose in BAC (89% each) but fell in stromally invasive tumour (31% and 17% respectively) (P < 0.01). Unlike in central bronchial carcinogenesis, loss of Fhit expression is a relatively late event in this putative progression of lung adenocarcinogenesis, and has potential as a surrogate marker of invasion, which could be of value in screening patients for lung cancer. Loss of CD44v6 expression follows the convention of failing adhesion molecule expression as malignancy develops. Increased expression of E-cadherin and beta-catenin may reflect increased cell-cell contact as tissue architecture changes in the transition from AAH to adenocarcinoma. Loss of MMP-2 and TIMP-2 in stromally invasive tumour may reflect a particular role for MMP-2 at the BAC stage, with later down-regulation of this particular enzyme. Copyright (C) 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley Sons, Ltd.

Original languageEnglish
Pages (from-to)638-644
Number of pages6
JournalThe Journal of pathology
Volume203
Issue number2
DOIs
Publication statusPublished - 2004

Keywords

  • lung cancer
  • pre-invasive lesions
  • adenocarcinoma
  • bronchioloalveolar carcinoma
  • atypical adenomatous hyperplasia
  • Fhit
  • MMP
  • E-cadherin
  • beta-catenin
  • adhesion molecules
  • PERIPHERAL LUNG ADENOCARCINOMA
  • E-CADHERIN
  • BETA-CATENIN
  • GENE ABNORMALITIES
  • TISSUE INHIBITOR
  • TUMOR INVASION
  • GAMMA-CATENIN
  • ALPHA-CATENIN
  • GELATINASE-A
  • CANCER

Cite this

Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma. / Kerr, K.m.; MacKenzie, S. J.; Murray, Graeme Ian; Nicolson, M. C.; King, George; Ramasami, S.; Fyfe, N.; Chapman, Andrea .d.

In: The Journal of pathology, Vol. 203, No. 2, 2004, p. 638-644.

Research output: Contribution to journalArticle

@article{0a9aaf6df0514c78a49cfc72693340c6,
title = "Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma",
abstract = "Invasive parenchymal-type lung adenocarcinoma develops from atypical adenomatous hyperplasia (AAH), through an intermediate in situ stage of bronchioloalveolar carcinoma (BAC). We examined the expression of the putative tumour suppressor gene product Fhit, cell adhesion molecules CD44v6, E-cadherin and beta-catenin, and matrix metalloproteinase 2 and its inhibitor, TIMP-2, in a range of AAH lesions, BACs and invasive adenocarcinomas, to determine the changes in molecular expression associated with this form of neoplastic progression. Sections of formalin-fixed wax-embedded archival tissue were stained by standard Immunohistochemical techniques and scored semi-quantitatively, resulting in a grading of negative/low- or high-level staining. Fhit protein was retained at high levels in over 90{\%} of AAH and 83{\%} of BAC, but was found in only 6{\%} of stromally invasive tumours (p < 0.0001). CD44v6 staining was high-level in 64{\%} of AAH but fell to 26{\%} in stromally invasive tumour (p = 0.007). E-cadherin and beta-catenin showed the opposite, with more highlevel staining as adenocarcinoma developed (p < 0.001). High-level MMP-2 and TIMP-2 expression was relatively infrequent in AAH (32{\%} and 40{\%} respectively), rose in BAC (89{\%} each) but fell in stromally invasive tumour (31{\%} and 17{\%} respectively) (P < 0.01). Unlike in central bronchial carcinogenesis, loss of Fhit expression is a relatively late event in this putative progression of lung adenocarcinogenesis, and has potential as a surrogate marker of invasion, which could be of value in screening patients for lung cancer. Loss of CD44v6 expression follows the convention of failing adhesion molecule expression as malignancy develops. Increased expression of E-cadherin and beta-catenin may reflect increased cell-cell contact as tissue architecture changes in the transition from AAH to adenocarcinoma. Loss of MMP-2 and TIMP-2 in stromally invasive tumour may reflect a particular role for MMP-2 at the BAC stage, with later down-regulation of this particular enzyme. Copyright (C) 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley Sons, Ltd.",
keywords = "lung cancer, pre-invasive lesions, adenocarcinoma, bronchioloalveolar carcinoma, atypical adenomatous hyperplasia, Fhit, MMP, E-cadherin, beta-catenin, adhesion molecules, PERIPHERAL LUNG ADENOCARCINOMA, E-CADHERIN, BETA-CATENIN, GENE ABNORMALITIES, TISSUE INHIBITOR, TUMOR INVASION, GAMMA-CATENIN, ALPHA-CATENIN, GELATINASE-A, CANCER",
author = "K.m. Kerr and MacKenzie, {S. J.} and Murray, {Graeme Ian} and Nicolson, {M. C.} and George King and S. Ramasami and N. Fyfe and Chapman, {Andrea .d.}",
year = "2004",
doi = "10.1002/path.1557",
language = "English",
volume = "203",
pages = "638--644",
journal = "The Journal of pathology",
issn = "0022-3417",
publisher = "Wiley",
number = "2",

}

TY - JOUR

T1 - Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma

AU - Kerr, K.m.

AU - MacKenzie, S. J.

AU - Murray, Graeme Ian

AU - Nicolson, M. C.

AU - King, George

AU - Ramasami, S.

AU - Fyfe, N.

AU - Chapman, Andrea .d.

PY - 2004

Y1 - 2004

N2 - Invasive parenchymal-type lung adenocarcinoma develops from atypical adenomatous hyperplasia (AAH), through an intermediate in situ stage of bronchioloalveolar carcinoma (BAC). We examined the expression of the putative tumour suppressor gene product Fhit, cell adhesion molecules CD44v6, E-cadherin and beta-catenin, and matrix metalloproteinase 2 and its inhibitor, TIMP-2, in a range of AAH lesions, BACs and invasive adenocarcinomas, to determine the changes in molecular expression associated with this form of neoplastic progression. Sections of formalin-fixed wax-embedded archival tissue were stained by standard Immunohistochemical techniques and scored semi-quantitatively, resulting in a grading of negative/low- or high-level staining. Fhit protein was retained at high levels in over 90% of AAH and 83% of BAC, but was found in only 6% of stromally invasive tumours (p < 0.0001). CD44v6 staining was high-level in 64% of AAH but fell to 26% in stromally invasive tumour (p = 0.007). E-cadherin and beta-catenin showed the opposite, with more highlevel staining as adenocarcinoma developed (p < 0.001). High-level MMP-2 and TIMP-2 expression was relatively infrequent in AAH (32% and 40% respectively), rose in BAC (89% each) but fell in stromally invasive tumour (31% and 17% respectively) (P < 0.01). Unlike in central bronchial carcinogenesis, loss of Fhit expression is a relatively late event in this putative progression of lung adenocarcinogenesis, and has potential as a surrogate marker of invasion, which could be of value in screening patients for lung cancer. Loss of CD44v6 expression follows the convention of failing adhesion molecule expression as malignancy develops. Increased expression of E-cadherin and beta-catenin may reflect increased cell-cell contact as tissue architecture changes in the transition from AAH to adenocarcinoma. Loss of MMP-2 and TIMP-2 in stromally invasive tumour may reflect a particular role for MMP-2 at the BAC stage, with later down-regulation of this particular enzyme. Copyright (C) 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley Sons, Ltd.

AB - Invasive parenchymal-type lung adenocarcinoma develops from atypical adenomatous hyperplasia (AAH), through an intermediate in situ stage of bronchioloalveolar carcinoma (BAC). We examined the expression of the putative tumour suppressor gene product Fhit, cell adhesion molecules CD44v6, E-cadherin and beta-catenin, and matrix metalloproteinase 2 and its inhibitor, TIMP-2, in a range of AAH lesions, BACs and invasive adenocarcinomas, to determine the changes in molecular expression associated with this form of neoplastic progression. Sections of formalin-fixed wax-embedded archival tissue were stained by standard Immunohistochemical techniques and scored semi-quantitatively, resulting in a grading of negative/low- or high-level staining. Fhit protein was retained at high levels in over 90% of AAH and 83% of BAC, but was found in only 6% of stromally invasive tumours (p < 0.0001). CD44v6 staining was high-level in 64% of AAH but fell to 26% in stromally invasive tumour (p = 0.007). E-cadherin and beta-catenin showed the opposite, with more highlevel staining as adenocarcinoma developed (p < 0.001). High-level MMP-2 and TIMP-2 expression was relatively infrequent in AAH (32% and 40% respectively), rose in BAC (89% each) but fell in stromally invasive tumour (31% and 17% respectively) (P < 0.01). Unlike in central bronchial carcinogenesis, loss of Fhit expression is a relatively late event in this putative progression of lung adenocarcinogenesis, and has potential as a surrogate marker of invasion, which could be of value in screening patients for lung cancer. Loss of CD44v6 expression follows the convention of failing adhesion molecule expression as malignancy develops. Increased expression of E-cadherin and beta-catenin may reflect increased cell-cell contact as tissue architecture changes in the transition from AAH to adenocarcinoma. Loss of MMP-2 and TIMP-2 in stromally invasive tumour may reflect a particular role for MMP-2 at the BAC stage, with later down-regulation of this particular enzyme. Copyright (C) 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley Sons, Ltd.

KW - lung cancer

KW - pre-invasive lesions

KW - adenocarcinoma

KW - bronchioloalveolar carcinoma

KW - atypical adenomatous hyperplasia

KW - Fhit

KW - MMP

KW - E-cadherin

KW - beta-catenin

KW - adhesion molecules

KW - PERIPHERAL LUNG ADENOCARCINOMA

KW - E-CADHERIN

KW - BETA-CATENIN

KW - GENE ABNORMALITIES

KW - TISSUE INHIBITOR

KW - TUMOR INVASION

KW - GAMMA-CATENIN

KW - ALPHA-CATENIN

KW - GELATINASE-A

KW - CANCER

U2 - 10.1002/path.1557

DO - 10.1002/path.1557

M3 - Article

VL - 203

SP - 638

EP - 644

JO - The Journal of pathology

JF - The Journal of pathology

SN - 0022-3417

IS - 2

ER -